France · Delayed Price · Currency is EUR Eurofins Scientific SE Earnings Call Transcripts
Fiscal Year 2026
-
Q1 revenue growth was hampered by severe weather, but March rebounded to mid-single digits. Management maintains full-year mid-single-digit organic growth guidance and expects continued margin improvement, supported by digitalization and portfolio optimization.
Fiscal Year 2025
-
Strong 2025 results with EPS up 24% and margins improving year-over-year, driven by digital investments and operational leverage. Biopharma and diagnostics are stabilizing, with significant growth expected post-2026. Ongoing share buybacks and robust cash flow support future M&A and shareholder returns.
-
Progress on network expansion and digitalization is on track, with margin improvements and strong cash flow expected. BioPharma and Life segments are performing well, while genomics and agroscience are stabilizing. FX headwinds are minor, and buybacks remain a capital allocation priority.
-
H1 2025 saw strong revenue, margin, and EPS growth, with mature business margins at target levels and ongoing investments in infrastructure and digitalization. Management remains confident in achieving 2027 targets, with biopharma recovery and further efficiency gains expected.
-
Q1 2025 delivered strong organic growth in food and environmental testing, with U.S. weather disruptions expected to be offset later in the year. Major Spanish acquisition and IT investments are underway, while guidance and capital allocation priorities remain unchanged.
Fiscal Year 2024
-
FY 2024 saw strong revenue and margin growth, with mature businesses nearing target profitability and free cash flow up 69%. While BioPharma and Agroscience were soft, long-term growth and margin targets are reaffirmed, and major investments are nearing completion.
-
Q3 saw softer growth due to BioPharma and Agroscience declines, but profitability and margins remained strong. Share buybacks increased as M&A slowed, and 2025 growth targets are reaffirmed, with BioPharma recovery expected in H2.
-
Strong H1 results with 6.5% revenue growth, 21% EBITDA increase, and 220 bps margin improvement, driven by operational efficiencies and digitalization. Biopharma softness seen as temporary; robust cash flow and balance sheet support continued investment and share buybacks.